Compare

Cero Therapeutics Holdings, Inc. vs Viskase Holdings, Inc. vs Scilex Holding Co vs Monte Rosa Therapeutics, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearCero Therapeutics Holdings, Inc.
CERO
Viskase Holdings, Inc.
VISKRevenue covers only part of its income (partial revenue)
Scilex Holding Co
SCLXRevenue covers only part of its income (partial revenue)
Monte Rosa Therapeutics, Inc.
GLUE
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenuen/an/a$30.25M$123.67M
Revenue growth (YoY)n/an/a-46.5%+63.5%
Gross marginn/an/a65.0% (computed)n/a
Operating marginn/an/an/m-43.8%
Net marginn/an/an/m-31.2%
Net income-$19.92M-$3.41M-$374.05M-$38.63M
EPS (Diluted)n/a-$0.07-$36.48n/a
Operating cash flow-$16.10M-$3.01M$3.82M-$22.80M
Free cash flown/an/a$3.68M-$27.50M
Cash & equivalentsn/a$42.57M$4.96M$129.88M
Total assets$3.64M$42.81M$364.98M$448.66M
Total liabilities$9.09Mn/a$576.73M$215.60M
Shareholders' equity-$5.45M-$2.52M-$207.78M$233.06M
Return on year-end equityn/an/an/a-16.6%
Shares outstandingn/a74.21M7.03M65.54M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearCero Therapeutics Holdings, Inc.Viskase Holdings, Inc.Scilex Holding CoMonte Rosa Therapeutics, Inc.
Latestn/an/an/a$123.67M
Ended 2025-12-31
1 year earliern/an/an/a$75.62M
Ended 2024-12-31
2 years earliern/an/an/a$0
Ended 2023-12-31
3 years earliern/an/an/an/a
4 years earliern/an/an/an/a